glycolaldehyde has been researched along with malondialdehyde in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Boufadi, MY; Dufrasne, F; Furtmüller, PG; Gelbcke, M; Meyer, F; Nève, J; Obinger, C; Soubhye, J; Van Antwerpen, P; Zouaoui Boudjeltia, K | 1 |
| He, RQ; Liu, Y; Qiang, M; Xu, YJ; Zhang, JL | 1 |
| Chait, A; den Hartigh, LJ; Gomes Kjerulf, D; Han, CY; Omer, M; Pathak, A; Shao, B; Subramanian, S; Tang, C; Wang, S | 1 |
3 other study(ies) available for glycolaldehyde and malondialdehyde
| Article | Year |
|---|---|
From Dynamic Combinatorial Chemistry to
Topics: | 2017 |
Reactive carbonyl compounds (RCCs) cause aggregation and dysfunction of fibrinogen.
Topics: Acetaldehyde; Acrolein; Blood Coagulation; Congo Red; Electrophoresis, Polyacrylamide Gel; Fibrinogen; Glyoxal; Humans; Malondialdehyde; Polymerization; Protein Carbonylation; Pyruvaldehyde; Solutions; Spectrometry, Fluorescence; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thrombin | 2012 |
Glycation of HDL blunts its anti-inflammatory and cholesterol efflux capacities in vitro, but has no effect in poorly controlled type 1 diabetes subjects.
Topics: Acetaldehyde; Apolipoprotein A-I; Apolipoprotein A-II; Cholesterol; Diabetes Mellitus, Type 1; Glucose; Glycosylation; Humans; Inflammation; Lipoproteins, HDL; Lysine; Malondialdehyde | 2020 |